Project Grant HT94252410433
Award Date
8/1/24
Completion Date
7/31/28
Dollars Obligated
$421K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas MD Anderson Cancer Center received a $647,995 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on image-guided bidirectional EphB4 agonist-based therapy for ovarian cancer. The award period runs from September 1, 2023 to August 31, 2027. As a leading cancer treatment and research institution, MD Anderson has extensive experience delivering a wide range of cancer-related...
This Project Grant award of $829,406 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Texas A&M Engineering Experiment Station (Tees) on "Platelet Pathophysiology in Resistance to Antiangiogenic Therapy Against Ovarian Cancer Evaluated in a Vascularized TME-Chip". The 4-year project, running from August 2024 to July 2028, will investigate the role of platelets in the tumor microenvironment and resistance to...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
This Project Grant award of $405,000.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Texas MD Anderson Cancer Center to target the novel TXNRD1-cGAS-SASP axis in order to eradicate stem-like cells in epithelial ovarian cancer. The 2-year project aims to transform health care for service members and the public through innovative and impactful cancer research. The University of Texas...
The Defense Health Agency awarded a $1,306,991 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The grant will fund a 4-year research project (8/1/2025 - 7/31/2029) focused on "ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA". The research aims to develop innovative approaches for the prevention, diagnosis, and treatment of cancer, with a focus on...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program provides $449,995.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on "CIRCULATING IMMUNE COMPLEXES AS BIOMARKERS FOR EARLY DETECTION AND MONITORING OF OVARIAN CANCER". The award period is from May 1, 2025 to April 30, 2029. As a leading academic cancer research institution, M.D. Anderson Cancer Center...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...